Peregrine Pays the Price

Well, that was quick.

Peregrine Pharmaceuticals (Nasdaq: PPHM  ) shares are diving once again this morning following an SEC filing disclosing what many investors already feared: It defaulted on a $30 million loan agreement entered into on Aug. 30. For those of you counting, that's less than a month from underwriting to default!

The loan -- which was underwritten by a consortium of lenders including Oxford Finance, Silicon Valley Bank, and MidCap Financial SBIC -- included a number of qualifying "events of default." Here's the legalese (emphasis added):

The Loan Agreement also includes events of default, including, among other things, payment defaults, breaches of representations, warranties or covenants, certain bankruptcy events, the failure to achieve a positive End of Phase II meeting by June 30, 2013 and certain material adverse changes, including a material impairment of the perfection or priority of the Lenders' lien.

Rewind back to Monday, and you might remember a 78% sell-off in shares after the company disclosed a critical error in its phase 2 data for lead drug candidate bavituximab. As you might expect, it wasn't hard for the lenders to argue that a "material adverse change" had occured.

Peregrine didn't object, and on Tuesday, it returned the $15 million it had drawn on the loan, along with accrued interest and a $975,000 "final payment fee." All told, the damage was right around $16 million. Assuming the company doesn't attempt to access capital through an equity offering, it now expects to have enough cash to operate through the end of April 2013, about seven months.

Foolish bottom line
Sure, Peregrine's revised phase 2 data might come back fine, and capitalizing on the panic could prove a big win for the speculative investor. However, making purely speculative bets isn't the true key to building long-term wealth. Holding on to companies positioned for long term success is the key, and we outline a few of them in our special free report "3 Stocks That Will Help You Retire Rich." Claim your instant copy of this complimentary report by clicking here now.

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2033724, ~/Articles/ArticleHandler.aspx, 7/22/2014 9:00:39 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement